首页 | 本学科首页   官方微博 | 高级检索  
     


Livedoid vasculopathy and high levels of lipoprotein (a): response to danazol
Authors:Paulo Ricardo Criado  Danielle Priscilia de Souza EspinelI  Neusayuriko Sakai Valentef  Afsaneh Alavi  Robert S. Kirsner
Affiliation:1. Dermatology, Dermatology Sao PauloHospital das Clínicas da Faculdade de Medicina da USP;2. Dermatology Department, S?o Paulo University, S?o Paulo, Brazil;3. Medicine (Dermatology), University of Toronto, Toronto, Ontario, Canada;4. Dermatology and Cutaneous Surgery, University of Miami, Miami, Florida
Abstract:Livedoid vasculopathy (LV) is a thrombo occlusive disorder presenting with recurrent painful ulcers of lower extremities. Association of LV with increased level of lipoprotein (a) (LP(a)), a risk factor for cardiovascular disease, has been reported. Danazol has been used with success in the management of LV, but none of the previous studies looked at the correlation between response to the treatment and level of LP(a). The aim of this study was to demonstrate the efficacy of low‐dose danazol in the treatment of LV and its effects on LP(a). We present four cases with LV who were successfully treated with low‐dose danazol, assessing the clinical characteristics and laboratory tests including the level of LP(a). The average age of the patients was 45 years and the mean duration of the disease was 19 years. The treatment regime of danazol 200 mg daily led to complete healing of ulcers and reduction in pain and a 70% (ranging from 52 to 87%) reduction in the level of LP(a). The limitation of this study is “small sample size.” In our patients with LV, low‐dose danazol led to clinical improvement along with significant reduction in the level of LP(a).
Keywords:pharmacology  skin signs of systemic disease  therapy‐systemic
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号